Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab Rechallenge vs Bevacizumab with Trifluridine/Tipiracil in mCRC
NCT07012954Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Jun 2025
- Primary completion
- Dec 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of cetuximab in metastatic colorectal cancer (mCRC), sponsored by Sun Yat-sen University. Started Jun 2025; status: recruiting.
02
Drugs
cetuximab
03
Conditions
metastatic colorectal cancer (mCRC)
Beyond the preview
Go deeper on NCT07012954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07012954.